https://traverseintel.com/analysis/cbp-detective-border-ai-transshipment-proof Traverse en 2026-08-13T19:13:08.156Z CBP's Detective Border Needs a Record Between Signal and Action https://traverseintel.com/analysis/germany-fixed-pharma-rebate-section-301-two-part-proof Traverse en 2026-08-13T13:53:26.949Z Germany's Fixed Pharma Rebate Splits USTR's Section 301 Proof in Two https://traverseintel.com/daily-brief/daily-brief-2026-08-13 Traverse en 2026-08-13T11:59:10.017Z 2026 CBAM Import Quarters Set 2027 Certificate Prices, Plus BIS and EXIM https://traverseintel.com/analysis/bis-export-license-delay-transparency-report-gap Traverse en 2026-08-13T03:12:02.820Z BIS Export License Report Leaves Delay Dates to Applicants https://traverseintel.com/analysis/cbam-2026-import-quarter-price-2027-certificates Traverse en 2026-08-13T03:08:40.551Z The 2026 Import Quarter Sets the Price for 2027 CBAM Certificates https://traverseintel.com/analysis/s4781-exim-default-rate-cap-portfolio-test Traverse en 2026-08-12T13:50:05.720Z S. 4781 Would Turn the EXIM Default Rate Cap Into a Portfolio Test https://traverseintel.com/daily-brief/daily-brief-2026-08-12 Traverse en 2026-08-12T12:03:44.811Z USMCA Withdrawal Scenario Raises Origin-Retesting Risk as Germany Section 301 Remedy Debate Widens https://traverseintel.com/analysis/germany-pharma-section-301-off-sector-tariffs Traverse en 2026-08-11T23:30:36.684Z Germany's Pharma Case Could Put Section 301 Tariffs on Other Goods